Looking after your profits - Dapagliflozin

As you will be aware, last month saw the launch Dapagliflozin following the patent expiry of the originator brand. The PSUK recommendation last month was for Dispensing Practices to continue using the originator brand with the associated MDS deal as the most profitable option.

From September 1st , Dapagliflozin has has been moved in to Category M and the reimbursement value has reduced, however the APM generic price has also been reducing in line with the market which now makes prescribing and dispensing the APM generic as the most profitable option for PSUK members.

If you intend to continue giving the brand to your patients, be sure to change the prescription to the brand name in order to be reimbursed for the higher price.

If you have any questions on this, or any other part of the PSUK proposition, please contact your account manager.